nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—CYP3A7—Sorafenib—thyroid cancer	0.092	0.166	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.092	0.166	CbGbCtD
Midazolam—CYP2B6—Sorafenib—thyroid cancer	0.0876	0.158	CbGbCtD
Midazolam—CYP3A5—Sorafenib—thyroid cancer	0.069	0.125	CbGbCtD
Midazolam—CYP2B6—Doxorubicin—thyroid cancer	0.0532	0.096	CbGbCtD
Midazolam—ABCB1—Sorafenib—thyroid cancer	0.0449	0.0811	CbGbCtD
Midazolam—CYP3A4—Vandetanib—thyroid cancer	0.0447	0.0806	CbGbCtD
Midazolam—Clonus—Vandetanib—thyroid cancer	0.0418	0.13	CcSEcCtD
Midazolam—ABCB1—Doxorubicin—thyroid cancer	0.0273	0.0492	CbGbCtD
Midazolam—CYP3A4—Sorafenib—thyroid cancer	0.0269	0.0486	CbGbCtD
Midazolam—CYP3A4—Doxorubicin—thyroid cancer	0.0163	0.0295	CbGbCtD
Midazolam—Cardio-respiratory arrest—Vandetanib—thyroid cancer	0.0135	0.0421	CcSEcCtD
Midazolam—Respiratory arrest—Vandetanib—thyroid cancer	0.011	0.0341	CcSEcCtD
Midazolam—CYP4B1—trachea—thyroid cancer	0.00539	0.0613	CbGeAlD
Midazolam—GABRA3—neck—thyroid cancer	0.00522	0.0593	CbGeAlD
Midazolam—Haematoma—Sorafenib—thyroid cancer	0.00517	0.0161	CcSEcCtD
Midazolam—Respiratory failure—Vandetanib—thyroid cancer	0.00491	0.0153	CcSEcCtD
Midazolam—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00465	0.0145	CcSEcCtD
Midazolam—CYP4B1—thyroid gland—thyroid cancer	0.00427	0.0485	CbGeAlD
Midazolam—Rhinorrhoea—Sorafenib—thyroid cancer	0.00401	0.0125	CcSEcCtD
Midazolam—Dysphonia—Sorafenib—thyroid cancer	0.00395	0.0123	CcSEcCtD
Midazolam—CYP4B1—head—thyroid cancer	0.00378	0.043	CbGeAlD
Midazolam—Warmth—Epirubicin—thyroid cancer	0.00378	0.0118	CcSEcCtD
Midazolam—Cardiac failure—Vandetanib—thyroid cancer	0.00359	0.0112	CcSEcCtD
Midazolam—Lethargy—Vandetanib—thyroid cancer	0.00357	0.0111	CcSEcCtD
Midazolam—GABRQ—head—thyroid cancer	0.00351	0.0399	CbGeAlD
Midazolam—GABRR3—head—thyroid cancer	0.00351	0.0399	CbGeAlD
Midazolam—Warmth—Doxorubicin—thyroid cancer	0.0035	0.0109	CcSEcCtD
Midazolam—Skin necrosis—Epirubicin—thyroid cancer	0.00344	0.0107	CcSEcCtD
Midazolam—Cardiac arrest—Vandetanib—thyroid cancer	0.00333	0.0104	CcSEcCtD
Midazolam—Skin necrosis—Doxorubicin—thyroid cancer	0.00318	0.00992	CcSEcCtD
Midazolam—Nasopharyngitis—Vandetanib—thyroid cancer	0.00313	0.00975	CcSEcCtD
Midazolam—Skin exfoliation—Sorafenib—thyroid cancer	0.0031	0.00967	CcSEcCtD
Midazolam—GABRG3—head—thyroid cancer	0.00308	0.035	CbGeAlD
Midazolam—GABRR2—head—thyroid cancer	0.00305	0.0346	CbGeAlD
Midazolam—GABRP—trachea—thyroid cancer	0.00304	0.0345	CbGeAlD
Midazolam—Bronchospasm—Vandetanib—thyroid cancer	0.00297	0.00927	CcSEcCtD
Midazolam—GABRR1—head—thyroid cancer	0.00293	0.0333	CbGeAlD
Midazolam—Depression—Vandetanib—thyroid cancer	0.00269	0.00838	CcSEcCtD
Midazolam—CYP4B1—lymph node—thyroid cancer	0.00265	0.0301	CbGeAlD
Midazolam—GABRD—head—thyroid cancer	0.00255	0.029	CbGeAlD
Midazolam—GABRA3—thyroid gland—thyroid cancer	0.00248	0.0282	CbGeAlD
Midazolam—Bradycardia—Vandetanib—thyroid cancer	0.00246	0.00768	CcSEcCtD
Midazolam—GABRG1—head—thyroid cancer	0.00245	0.0279	CbGeAlD
Midazolam—GABRA6—head—thyroid cancer	0.00244	0.0277	CbGeAlD
Midazolam—Cardiac failure—Sorafenib—thyroid cancer	0.00242	0.00754	CcSEcCtD
Midazolam—GABRB1—head—thyroid cancer	0.00238	0.027	CbGeAlD
Midazolam—GABRA5—head—thyroid cancer	0.00237	0.0269	CbGeAlD
Midazolam—Visual impairment—Vandetanib—thyroid cancer	0.00233	0.00727	CcSEcCtD
Midazolam—GABRE—trachea—thyroid cancer	0.00232	0.0263	CbGeAlD
Midazolam—Eye disorder—Vandetanib—thyroid cancer	0.00226	0.00705	CcSEcCtD
Midazolam—Cardiac disorder—Vandetanib—thyroid cancer	0.00225	0.007	CcSEcCtD
Midazolam—Mood swings—Sorafenib—thyroid cancer	0.00224	0.00697	CcSEcCtD
Midazolam—GABRA3—head—thyroid cancer	0.0022	0.025	CbGeAlD
Midazolam—Mediastinal disorder—Vandetanib—thyroid cancer	0.00218	0.0068	CcSEcCtD
Midazolam—Local reaction—Epirubicin—thyroid cancer	0.00217	0.00676	CcSEcCtD
Midazolam—GABRA4—head—thyroid cancer	0.00215	0.0244	CbGeAlD
Midazolam—GABRR2—lymph node—thyroid cancer	0.00213	0.0242	CbGeAlD
Midazolam—GABRP—head—thyroid cancer	0.00213	0.0242	CbGeAlD
Midazolam—Mental disorder—Vandetanib—thyroid cancer	0.00212	0.00661	CcSEcCtD
Midazolam—Nasopharyngitis—Sorafenib—thyroid cancer	0.00211	0.00658	CcSEcCtD
Midazolam—Local reaction—Doxorubicin—thyroid cancer	0.00201	0.00626	CcSEcCtD
Midazolam—Vision blurred—Vandetanib—thyroid cancer	0.00199	0.00619	CcSEcCtD
Midazolam—Tremor—Vandetanib—thyroid cancer	0.00197	0.00615	CcSEcCtD
Midazolam—Cough—Vandetanib—thyroid cancer	0.00184	0.00573	CcSEcCtD
Midazolam—GABRE—thyroid gland—thyroid cancer	0.00183	0.0208	CbGeAlD
Midazolam—GABRB2—head—thyroid cancer	0.0018	0.0204	CbGeAlD
Midazolam—GABRG2—head—thyroid cancer	0.0018	0.0204	CbGeAlD
Midazolam—Anxiety—Vandetanib—thyroid cancer	0.00179	0.00557	CcSEcCtD
Midazolam—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00178	0.00556	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00178	0.00555	CcSEcCtD
Midazolam—Redness—Epirubicin—thyroid cancer	0.00178	0.00555	CcSEcCtD
Midazolam—Dry mouth—Vandetanib—thyroid cancer	0.00175	0.00547	CcSEcCtD
Midazolam—Hyperventilation—Epirubicin—thyroid cancer	0.00175	0.00544	CcSEcCtD
Midazolam—Thrombosis—Epirubicin—thyroid cancer	0.0017	0.00529	CcSEcCtD
Midazolam—Nervous system disorder—Vandetanib—thyroid cancer	0.00169	0.00525	CcSEcCtD
Midazolam—Nystagmus—Epirubicin—thyroid cancer	0.00168	0.00524	CcSEcCtD
Midazolam—Skin disorder—Vandetanib—thyroid cancer	0.00167	0.0052	CcSEcCtD
Midazolam—Redness—Doxorubicin—thyroid cancer	0.00165	0.00513	CcSEcCtD
Midazolam—GABRA2—head—thyroid cancer	0.00164	0.0186	CbGeAlD
Midazolam—GABRE—head—thyroid cancer	0.00163	0.0185	CbGeAlD
Midazolam—Hyperventilation—Doxorubicin—thyroid cancer	0.00162	0.00503	CcSEcCtD
Midazolam—Connective tissue disorder—Sorafenib—thyroid cancer	0.0016	0.005	CcSEcCtD
Midazolam—GABRA1—head—thyroid cancer	0.00159	0.018	CbGeAlD
Midazolam—Thrombosis—Doxorubicin—thyroid cancer	0.00157	0.00489	CcSEcCtD
Midazolam—Nystagmus—Doxorubicin—thyroid cancer	0.00156	0.00485	CcSEcCtD
Midazolam—GABRB3—thyroid gland—thyroid cancer	0.00155	0.0177	CbGeAlD
Midazolam—SLC22A1—head—thyroid cancer	0.00155	0.0176	CbGeAlD
Midazolam—Paraesthesia—Vandetanib—thyroid cancer	0.00154	0.00481	CcSEcCtD
Midazolam—Dyspnoea—Vandetanib—thyroid cancer	0.00153	0.00478	CcSEcCtD
Midazolam—Feeling hot—Epirubicin—thyroid cancer	0.00153	0.00477	CcSEcCtD
Midazolam—Cardiac disorder—Sorafenib—thyroid cancer	0.00152	0.00472	CcSEcCtD
Midazolam—Dyspepsia—Vandetanib—thyroid cancer	0.00151	0.00472	CcSEcCtD
Midazolam—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00148	0.00463	CcSEcCtD
Midazolam—Fatigue—Vandetanib—thyroid cancer	0.00148	0.00462	CcSEcCtD
Midazolam—Immune system disorder—Sorafenib—thyroid cancer	0.00147	0.0046	CcSEcCtD
Midazolam—Injection site pain—Epirubicin—thyroid cancer	0.00147	0.00459	CcSEcCtD
Midazolam—Mediastinal disorder—Sorafenib—thyroid cancer	0.00147	0.00459	CcSEcCtD
Midazolam—Pain—Vandetanib—thyroid cancer	0.00147	0.00458	CcSEcCtD
Midazolam—Constipation—Vandetanib—thyroid cancer	0.00147	0.00458	CcSEcCtD
Midazolam—Dysphonia—Epirubicin—thyroid cancer	0.00146	0.00455	CcSEcCtD
Midazolam—Mental disorder—Sorafenib—thyroid cancer	0.00143	0.00446	CcSEcCtD
Midazolam—Erythema—Sorafenib—thyroid cancer	0.00142	0.00443	CcSEcCtD
Midazolam—Feeling hot—Doxorubicin—thyroid cancer	0.00142	0.00441	CcSEcCtD
Midazolam—Delirium—Epirubicin—thyroid cancer	0.0014	0.00435	CcSEcCtD
Midazolam—GABRB3—head—thyroid cancer	0.00138	0.0157	CbGeAlD
Midazolam—Injection site pain—Doxorubicin—thyroid cancer	0.00136	0.00424	CcSEcCtD
Midazolam—Dysphonia—Doxorubicin—thyroid cancer	0.00135	0.00421	CcSEcCtD
Midazolam—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00133	0.00415	CcSEcCtD
Midazolam—Delirium—Doxorubicin—thyroid cancer	0.00129	0.00403	CcSEcCtD
Midazolam—Dyskinesia—Epirubicin—thyroid cancer	0.00128	0.00398	CcSEcCtD
Midazolam—Syncope—Sorafenib—thyroid cancer	0.00127	0.00397	CcSEcCtD
Midazolam—Dysarthria—Epirubicin—thyroid cancer	0.00127	0.00396	CcSEcCtD
Midazolam—Cough—Sorafenib—thyroid cancer	0.00124	0.00386	CcSEcCtD
Midazolam—Asthenia—Vandetanib—thyroid cancer	0.00123	0.00384	CcSEcCtD
Midazolam—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00123	0.00384	CcSEcCtD
Midazolam—Pruritus—Vandetanib—thyroid cancer	0.00122	0.00379	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0012	0.00374	CcSEcCtD
Midazolam—Ventricular tachycardia—Epirubicin—thyroid cancer	0.0012	0.00374	CcSEcCtD
Midazolam—Hiccups—Epirubicin—thyroid cancer	0.0012	0.00374	CcSEcCtD
Midazolam—Dry mouth—Sorafenib—thyroid cancer	0.00118	0.00369	CcSEcCtD
Midazolam—Dyskinesia—Doxorubicin—thyroid cancer	0.00118	0.00369	CcSEcCtD
Midazolam—Dysarthria—Doxorubicin—thyroid cancer	0.00118	0.00366	CcSEcCtD
Midazolam—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00117	0.00364	CcSEcCtD
Midazolam—Anaphylactic shock—Sorafenib—thyroid cancer	0.00116	0.00361	CcSEcCtD
Midazolam—GABRA2—lymph node—thyroid cancer	0.00115	0.0131	CbGeAlD
Midazolam—Skin exfoliation—Epirubicin—thyroid cancer	0.00115	0.00357	CcSEcCtD
Midazolam—Shock—Sorafenib—thyroid cancer	0.00114	0.00356	CcSEcCtD
Midazolam—GABRE—lymph node—thyroid cancer	0.00114	0.0129	CbGeAlD
Midazolam—Nervous system disorder—Sorafenib—thyroid cancer	0.00114	0.00354	CcSEcCtD
Midazolam—Dizziness—Vandetanib—thyroid cancer	0.00114	0.00354	CcSEcCtD
Midazolam—Skin disorder—Sorafenib—thyroid cancer	0.00113	0.00351	CcSEcCtD
Midazolam—Hiccups—Doxorubicin—thyroid cancer	0.00111	0.00346	CcSEcCtD
Midazolam—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00111	0.00346	CcSEcCtD
Midazolam—Vomiting—Vandetanib—thyroid cancer	0.00109	0.00341	CcSEcCtD
Midazolam—Rash—Vandetanib—thyroid cancer	0.00108	0.00338	CcSEcCtD
Midazolam—Dermatitis—Vandetanib—thyroid cancer	0.00108	0.00338	CcSEcCtD
Midazolam—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00108	0.00336	CcSEcCtD
Midazolam—Headache—Vandetanib—thyroid cancer	0.00108	0.00336	CcSEcCtD
Midazolam—Skin exfoliation—Doxorubicin—thyroid cancer	0.00106	0.00331	CcSEcCtD
Midazolam—Dyspnoea—Sorafenib—thyroid cancer	0.00103	0.00322	CcSEcCtD
Midazolam—Nausea—Vandetanib—thyroid cancer	0.00102	0.00318	CcSEcCtD
Midazolam—Dyspepsia—Sorafenib—thyroid cancer	0.00102	0.00318	CcSEcCtD
Midazolam—Phlebitis—Epirubicin—thyroid cancer	0.00101	0.00315	CcSEcCtD
Midazolam—Thrombophlebitis—Epirubicin—thyroid cancer	0.00101	0.00314	CcSEcCtD
Midazolam—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.001	0.00312	CcSEcCtD
Midazolam—Fatigue—Sorafenib—thyroid cancer	0.001	0.00312	CcSEcCtD
Midazolam—Constipation—Sorafenib—thyroid cancer	0.000992	0.00309	CcSEcCtD
Midazolam—Pain—Sorafenib—thyroid cancer	0.000992	0.00309	CcSEcCtD
Midazolam—CYP2E1—thyroid gland—thyroid cancer	0.000989	0.0112	CbGeAlD
Midazolam—Phlebitis—Doxorubicin—thyroid cancer	0.000937	0.00292	CcSEcCtD
Midazolam—CYP2B6—head—thyroid cancer	0.000935	0.0106	CbGeAlD
Midazolam—Thrombophlebitis—Doxorubicin—thyroid cancer	0.000932	0.00291	CcSEcCtD
Midazolam—Urticaria—Sorafenib—thyroid cancer	0.000922	0.00287	CcSEcCtD
Midazolam—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000901	0.00281	CcSEcCtD
Midazolam—Cardiac failure—Epirubicin—thyroid cancer	0.000894	0.00279	CcSEcCtD
Midazolam—Lethargy—Epirubicin—thyroid cancer	0.00089	0.00277	CcSEcCtD
Midazolam—CYP2E1—head—thyroid cancer	0.000877	0.00997	CbGeAlD
Midazolam—Osteoarthritis—Epirubicin—thyroid cancer	0.000872	0.00272	CcSEcCtD
Midazolam—Diplopia—Epirubicin—thyroid cancer	0.000872	0.00272	CcSEcCtD
Midazolam—Affect lability—Epirubicin—thyroid cancer	0.000859	0.00268	CcSEcCtD
Midazolam—Hypersensitivity—Sorafenib—thyroid cancer	0.000855	0.00266	CcSEcCtD
Midazolam—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000834	0.0026	CcSEcCtD
Midazolam—Asthenia—Sorafenib—thyroid cancer	0.000832	0.00259	CcSEcCtD
Midazolam—Cardiac arrest—Epirubicin—thyroid cancer	0.000829	0.00258	CcSEcCtD
Midazolam—Cardiac failure—Doxorubicin—thyroid cancer	0.000827	0.00258	CcSEcCtD
Midazolam—Mood swings—Epirubicin—thyroid cancer	0.000826	0.00257	CcSEcCtD
Midazolam—Lethargy—Doxorubicin—thyroid cancer	0.000824	0.00257	CcSEcCtD
Midazolam—Pruritus—Sorafenib—thyroid cancer	0.000821	0.00256	CcSEcCtD
Midazolam—Ataxia—Epirubicin—thyroid cancer	0.00082	0.00256	CcSEcCtD
Midazolam—Osteoarthritis—Doxorubicin—thyroid cancer	0.000807	0.00251	CcSEcCtD
Midazolam—Diplopia—Doxorubicin—thyroid cancer	0.000807	0.00251	CcSEcCtD
Midazolam—Affect lability—Doxorubicin—thyroid cancer	0.000794	0.00248	CcSEcCtD
Midazolam—Nasopharyngitis—Epirubicin—thyroid cancer	0.00078	0.00243	CcSEcCtD
Midazolam—Muscular weakness—Epirubicin—thyroid cancer	0.000769	0.0024	CcSEcCtD
Midazolam—Cardiac arrest—Doxorubicin—thyroid cancer	0.000767	0.00239	CcSEcCtD
Midazolam—Dizziness—Sorafenib—thyroid cancer	0.000767	0.00239	CcSEcCtD
Midazolam—Mood swings—Doxorubicin—thyroid cancer	0.000765	0.00238	CcSEcCtD
Midazolam—Ataxia—Doxorubicin—thyroid cancer	0.000759	0.00236	CcSEcCtD
Midazolam—Vomiting—Sorafenib—thyroid cancer	0.000738	0.0023	CcSEcCtD
Midazolam—Rash—Sorafenib—thyroid cancer	0.000731	0.00228	CcSEcCtD
Midazolam—Dermatitis—Sorafenib—thyroid cancer	0.000731	0.00228	CcSEcCtD
Midazolam—Headache—Sorafenib—thyroid cancer	0.000727	0.00226	CcSEcCtD
Midazolam—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000722	0.00225	CcSEcCtD
Midazolam—Muscular weakness—Doxorubicin—thyroid cancer	0.000712	0.00222	CcSEcCtD
Midazolam—ABCB1—trachea—thyroid cancer	0.000712	0.00809	CbGeAlD
Midazolam—Nausea—Sorafenib—thyroid cancer	0.000689	0.00215	CcSEcCtD
Midazolam—Drowsiness—Epirubicin—thyroid cancer	0.000672	0.00209	CcSEcCtD
Midazolam—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000659	0.00205	CcSEcCtD
Midazolam—Drowsiness—Doxorubicin—thyroid cancer	0.000622	0.00194	CcSEcCtD
Midazolam—Bradycardia—Epirubicin—thyroid cancer	0.000614	0.00191	CcSEcCtD
Midazolam—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00061	0.0019	CcSEcCtD
Midazolam—Connective tissue disorder—Epirubicin—thyroid cancer	0.000593	0.00185	CcSEcCtD
Midazolam—Visual impairment—Epirubicin—thyroid cancer	0.000582	0.00181	CcSEcCtD
Midazolam—Bradycardia—Doxorubicin—thyroid cancer	0.000568	0.00177	CcSEcCtD
Midazolam—Eye disorder—Epirubicin—thyroid cancer	0.000564	0.00176	CcSEcCtD
Midazolam—ABCB1—thyroid gland—thyroid cancer	0.000563	0.0064	CbGeAlD
Midazolam—Cardiac disorder—Epirubicin—thyroid cancer	0.00056	0.00175	CcSEcCtD
Midazolam—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000549	0.00171	CcSEcCtD
Midazolam—Immune system disorder—Epirubicin—thyroid cancer	0.000545	0.0017	CcSEcCtD
Midazolam—Mediastinal disorder—Epirubicin—thyroid cancer	0.000544	0.00169	CcSEcCtD
Midazolam—Chills—Epirubicin—thyroid cancer	0.000541	0.00169	CcSEcCtD
Midazolam—Visual impairment—Doxorubicin—thyroid cancer	0.000538	0.00168	CcSEcCtD
Midazolam—Mental disorder—Epirubicin—thyroid cancer	0.000529	0.00165	CcSEcCtD
Midazolam—Erythema—Epirubicin—thyroid cancer	0.000525	0.00164	CcSEcCtD
Midazolam—Eye disorder—Doxorubicin—thyroid cancer	0.000522	0.00163	CcSEcCtD
Midazolam—Cardiac disorder—Doxorubicin—thyroid cancer	0.000518	0.00161	CcSEcCtD
Midazolam—Tension—Epirubicin—thyroid cancer	0.000516	0.00161	CcSEcCtD
Midazolam—Nervousness—Epirubicin—thyroid cancer	0.00051	0.00159	CcSEcCtD
Midazolam—Immune system disorder—Doxorubicin—thyroid cancer	0.000504	0.00157	CcSEcCtD
Midazolam—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000503	0.00157	CcSEcCtD
Midazolam—Chills—Doxorubicin—thyroid cancer	0.000501	0.00156	CcSEcCtD
Midazolam—ABCB1—head—thyroid cancer	0.0005	0.00568	CbGeAlD
Midazolam—Vision blurred—Epirubicin—thyroid cancer	0.000495	0.00154	CcSEcCtD
Midazolam—Mental disorder—Doxorubicin—thyroid cancer	0.000489	0.00152	CcSEcCtD
Midazolam—Erythema—Doxorubicin—thyroid cancer	0.000486	0.00151	CcSEcCtD
Midazolam—Agitation—Epirubicin—thyroid cancer	0.000483	0.0015	CcSEcCtD
Midazolam—Tension—Doxorubicin—thyroid cancer	0.000477	0.00149	CcSEcCtD
Midazolam—Nervousness—Doxorubicin—thyroid cancer	0.000472	0.00147	CcSEcCtD
Midazolam—Vertigo—Epirubicin—thyroid cancer	0.000472	0.00147	CcSEcCtD
Midazolam—Syncope—Epirubicin—thyroid cancer	0.000471	0.00147	CcSEcCtD
Midazolam—Cough—Epirubicin—thyroid cancer	0.000458	0.00143	CcSEcCtD
Midazolam—Vision blurred—Doxorubicin—thyroid cancer	0.000458	0.00143	CcSEcCtD
Midazolam—Agitation—Doxorubicin—thyroid cancer	0.000447	0.00139	CcSEcCtD
Midazolam—Anxiety—Epirubicin—thyroid cancer	0.000446	0.00139	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000444	0.00138	CcSEcCtD
Midazolam—Dry mouth—Epirubicin—thyroid cancer	0.000437	0.00136	CcSEcCtD
Midazolam—Vertigo—Doxorubicin—thyroid cancer	0.000437	0.00136	CcSEcCtD
Midazolam—Syncope—Doxorubicin—thyroid cancer	0.000436	0.00136	CcSEcCtD
Midazolam—Confusional state—Epirubicin—thyroid cancer	0.000432	0.00135	CcSEcCtD
Midazolam—Anaphylactic shock—Epirubicin—thyroid cancer	0.000429	0.00134	CcSEcCtD
Midazolam—Cough—Doxorubicin—thyroid cancer	0.000424	0.00132	CcSEcCtD
Midazolam—Shock—Epirubicin—thyroid cancer	0.000422	0.00131	CcSEcCtD
Midazolam—Nervous system disorder—Epirubicin—thyroid cancer	0.00042	0.00131	CcSEcCtD
Midazolam—Tachycardia—Epirubicin—thyroid cancer	0.000418	0.0013	CcSEcCtD
Midazolam—Skin disorder—Epirubicin—thyroid cancer	0.000416	0.0013	CcSEcCtD
Midazolam—Anxiety—Doxorubicin—thyroid cancer	0.000412	0.00128	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000411	0.00128	CcSEcCtD
Midazolam—Dry mouth—Doxorubicin—thyroid cancer	0.000405	0.00126	CcSEcCtD
Midazolam—Hypotension—Epirubicin—thyroid cancer	0.000401	0.00125	CcSEcCtD
Midazolam—Confusional state—Doxorubicin—thyroid cancer	0.0004	0.00125	CcSEcCtD
Midazolam—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000397	0.00124	CcSEcCtD
Midazolam—Shock—Doxorubicin—thyroid cancer	0.00039	0.00122	CcSEcCtD
Midazolam—Nervous system disorder—Doxorubicin—thyroid cancer	0.000389	0.00121	CcSEcCtD
Midazolam—Tachycardia—Doxorubicin—thyroid cancer	0.000387	0.00121	CcSEcCtD
Midazolam—Skin disorder—Doxorubicin—thyroid cancer	0.000385	0.0012	CcSEcCtD
Midazolam—Paraesthesia—Epirubicin—thyroid cancer	0.000385	0.0012	CcSEcCtD
Midazolam—Dyspnoea—Epirubicin—thyroid cancer	0.000382	0.00119	CcSEcCtD
Midazolam—Somnolence—Epirubicin—thyroid cancer	0.000381	0.00119	CcSEcCtD
Midazolam—Dyspepsia—Epirubicin—thyroid cancer	0.000377	0.00118	CcSEcCtD
Midazolam—Hypotension—Doxorubicin—thyroid cancer	0.000371	0.00115	CcSEcCtD
Midazolam—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00037	0.00115	CcSEcCtD
Midazolam—Fatigue—Epirubicin—thyroid cancer	0.00037	0.00115	CcSEcCtD
Midazolam—Pain—Epirubicin—thyroid cancer	0.000367	0.00114	CcSEcCtD
Midazolam—Constipation—Epirubicin—thyroid cancer	0.000367	0.00114	CcSEcCtD
Midazolam—Paraesthesia—Doxorubicin—thyroid cancer	0.000356	0.00111	CcSEcCtD
Midazolam—Dyspnoea—Doxorubicin—thyroid cancer	0.000354	0.0011	CcSEcCtD
Midazolam—Feeling abnormal—Epirubicin—thyroid cancer	0.000353	0.0011	CcSEcCtD
Midazolam—Somnolence—Doxorubicin—thyroid cancer	0.000353	0.0011	CcSEcCtD
Midazolam—ABCB1—lymph node—thyroid cancer	0.00035	0.00398	CbGeAlD
Midazolam—Dyspepsia—Doxorubicin—thyroid cancer	0.000349	0.00109	CcSEcCtD
Midazolam—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000342	0.00107	CcSEcCtD
Midazolam—Fatigue—Doxorubicin—thyroid cancer	0.000342	0.00107	CcSEcCtD
Midazolam—Urticaria—Epirubicin—thyroid cancer	0.000341	0.00106	CcSEcCtD
Midazolam—Pain—Doxorubicin—thyroid cancer	0.000339	0.00106	CcSEcCtD
Midazolam—Constipation—Doxorubicin—thyroid cancer	0.000339	0.00106	CcSEcCtD
Midazolam—Feeling abnormal—Doxorubicin—thyroid cancer	0.000327	0.00102	CcSEcCtD
Midazolam—Hypersensitivity—Epirubicin—thyroid cancer	0.000316	0.000984	CcSEcCtD
Midazolam—Urticaria—Doxorubicin—thyroid cancer	0.000315	0.000982	CcSEcCtD
Midazolam—Asthenia—Epirubicin—thyroid cancer	0.000308	0.000958	CcSEcCtD
Midazolam—Pruritus—Epirubicin—thyroid cancer	0.000303	0.000945	CcSEcCtD
Midazolam—Hypersensitivity—Doxorubicin—thyroid cancer	0.000292	0.000911	CcSEcCtD
Midazolam—Asthenia—Doxorubicin—thyroid cancer	0.000285	0.000887	CcSEcCtD
Midazolam—Dizziness—Epirubicin—thyroid cancer	0.000284	0.000883	CcSEcCtD
Midazolam—Pruritus—Doxorubicin—thyroid cancer	0.000281	0.000875	CcSEcCtD
Midazolam—Vomiting—Epirubicin—thyroid cancer	0.000273	0.000849	CcSEcCtD
Midazolam—Rash—Epirubicin—thyroid cancer	0.00027	0.000842	CcSEcCtD
Midazolam—Dermatitis—Epirubicin—thyroid cancer	0.00027	0.000842	CcSEcCtD
Midazolam—Headache—Epirubicin—thyroid cancer	0.000269	0.000837	CcSEcCtD
Midazolam—Dizziness—Doxorubicin—thyroid cancer	0.000262	0.000817	CcSEcCtD
Midazolam—Nausea—Epirubicin—thyroid cancer	0.000255	0.000793	CcSEcCtD
Midazolam—Vomiting—Doxorubicin—thyroid cancer	0.000252	0.000786	CcSEcCtD
Midazolam—Rash—Doxorubicin—thyroid cancer	0.00025	0.000779	CcSEcCtD
Midazolam—Dermatitis—Doxorubicin—thyroid cancer	0.00025	0.000779	CcSEcCtD
Midazolam—Headache—Doxorubicin—thyroid cancer	0.000249	0.000774	CcSEcCtD
Midazolam—Nausea—Doxorubicin—thyroid cancer	0.000236	0.000734	CcSEcCtD
Midazolam—GABRA4—Transmembrane transport of small molecules—CP—thyroid cancer	8.9e-05	0.0024	CbGpPWpGaD
Midazolam—GABRA6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.87e-05	0.00239	CbGpPWpGaD
Midazolam—GABRR1—Neuronal System—BRAF—thyroid cancer	8.85e-05	0.00238	CbGpPWpGaD
Midazolam—GABRR2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.79e-05	0.00237	CbGpPWpGaD
Midazolam—GABRQ—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.79e-05	0.00237	CbGpPWpGaD
Midazolam—GABRA4—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.75e-05	0.00236	CbGpPWpGaD
Midazolam—GABRA6—Transmission across Chemical Synapses—BRAF—thyroid cancer	8.46e-05	0.00228	CbGpPWpGaD
Midazolam—GABRQ—Neuronal System—BRAF—thyroid cancer	8.45e-05	0.00227	CbGpPWpGaD
Midazolam—GABRR2—Neuronal System—BRAF—thyroid cancer	8.45e-05	0.00227	CbGpPWpGaD
Midazolam—GABRA4—Transmission across Chemical Synapses—BRAF—thyroid cancer	8.35e-05	0.00225	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	8.27e-05	0.00223	CbGpPWpGaD
Midazolam—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	8.2e-05	0.00221	CbGpPWpGaD
Midazolam—GABRB2—Transmembrane transport of small molecules—CP—thyroid cancer	8.14e-05	0.00219	CbGpPWpGaD
Midazolam—GABRB2—Transmembrane transport of small molecules—TPR—thyroid cancer	8.14e-05	0.00219	CbGpPWpGaD
Midazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	8.13e-05	0.00219	CbGpPWpGaD
Midazolam—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	8.04e-05	0.00216	CbGpPWpGaD
Midazolam—GABRB2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.01e-05	0.00216	CbGpPWpGaD
Midazolam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	8e-05	0.00215	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—TPR—thyroid cancer	7.91e-05	0.00213	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—CP—thyroid cancer	7.91e-05	0.00213	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.78e-05	0.00209	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—TPR—thyroid cancer	7.76e-05	0.00209	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—CP—thyroid cancer	7.76e-05	0.00209	CbGpPWpGaD
Midazolam—GABRR1—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.74e-05	0.00208	CbGpPWpGaD
Midazolam—GABRB2—Transmission across Chemical Synapses—BRAF—thyroid cancer	7.64e-05	0.00206	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.64e-05	0.00206	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—CP—thyroid cancer	7.63e-05	0.00205	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—TPR—thyroid cancer	7.63e-05	0.00205	CbGpPWpGaD
Midazolam—CYP2B6—Biological oxidations—RXRA—thyroid cancer	7.62e-05	0.00205	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—CP—thyroid cancer	7.58e-05	0.00204	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—TPR—thyroid cancer	7.58e-05	0.00204	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—MINPP1—thyroid cancer	7.57e-05	0.00204	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.51e-05	0.00202	CbGpPWpGaD
Midazolam—CYP2E1—Biological oxidations—RXRA—thyroid cancer	7.46e-05	0.00201	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.46e-05	0.00201	CbGpPWpGaD
Midazolam—CYP3A5—Biological oxidations—RXRA—thyroid cancer	7.45e-05	0.00201	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—CP—thyroid cancer	7.44e-05	0.002	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—TPR—thyroid cancer	7.44e-05	0.002	CbGpPWpGaD
Midazolam—GABRA5—Transmission across Chemical Synapses—BRAF—thyroid cancer	7.42e-05	0.002	CbGpPWpGaD
Midazolam—GABRR2—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.38e-05	0.00199	CbGpPWpGaD
Midazolam—GABRQ—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.38e-05	0.00199	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.32e-05	0.00197	CbGpPWpGaD
Midazolam—GABRA3—Transmission across Chemical Synapses—BRAF—thyroid cancer	7.29e-05	0.00196	CbGpPWpGaD
Midazolam—GABRG3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.24e-05	0.00195	CbGpPWpGaD
Midazolam—GABRA2—Transmission across Chemical Synapses—BRAF—thyroid cancer	7.16e-05	0.00193	CbGpPWpGaD
Midazolam—GABRB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.13e-05	0.00192	CbGpPWpGaD
Midazolam—GABRB3—Transmission across Chemical Synapses—BRAF—thyroid cancer	7.12e-05	0.00192	CbGpPWpGaD
Midazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	7.07e-05	0.0019	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—MINPP1—thyroid cancer	7.05e-05	0.0019	CbGpPWpGaD
Midazolam—GABRG2—Transmission across Chemical Synapses—BRAF—thyroid cancer	6.99e-05	0.00188	CbGpPWpGaD
Midazolam—GABRG3—Neuronal System—BRAF—thyroid cancer	6.96e-05	0.00187	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—SLC5A5—thyroid cancer	6.94e-05	0.00187	CbGpPWpGaD
Midazolam—GABRB1—Neuronal System—BRAF—thyroid cancer	6.85e-05	0.00184	CbGpPWpGaD
Midazolam—GABRA6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.75e-05	0.00182	CbGpPWpGaD
Midazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	6.74e-05	0.00181	CbGpPWpGaD
Midazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	6.74e-05	0.00181	CbGpPWpGaD
Midazolam—GABRA4—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.66e-05	0.00179	CbGpPWpGaD
Midazolam—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	6.52e-05	0.00176	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—TPR—thyroid cancer	6.51e-05	0.00175	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—CP—thyroid cancer	6.51e-05	0.00175	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.5e-05	0.00175	CbGpPWpGaD
Midazolam—GABRA6—Neuronal System—BRAF—thyroid cancer	6.48e-05	0.00175	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NDUFA13—thyroid cancer	6.44e-05	0.00173	CbGpPWpGaD
Midazolam—GABRA4—Neuronal System—BRAF—thyroid cancer	6.4e-05	0.00172	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.4e-05	0.00172	CbGpPWpGaD
Midazolam—GABRA1—Transmission across Chemical Synapses—BRAF—thyroid cancer	6.11e-05	0.00164	CbGpPWpGaD
Midazolam—GABRB2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.09e-05	0.00164	CbGpPWpGaD
Midazolam—GABRG3—Transmembrane transport of small molecules—RXRA—thyroid cancer	6.08e-05	0.00164	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CHST14—thyroid cancer	6.05e-05	0.00163	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NDUFA13—thyroid cancer	5.99e-05	0.00161	CbGpPWpGaD
Midazolam—GABRB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.99e-05	0.00161	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.92e-05	0.00159	CbGpPWpGaD
Midazolam—GABRB2—Neuronal System—BRAF—thyroid cancer	5.85e-05	0.00158	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—RXRA—thyroid cancer	5.83e-05	0.00157	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.81e-05	0.00156	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—TPR—thyroid cancer	5.8e-05	0.00156	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.71e-05	0.00154	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PRKAR1A—thyroid cancer	5.71e-05	0.00154	CbGpPWpGaD
Midazolam—GABRA5—Neuronal System—BRAF—thyroid cancer	5.69e-05	0.00153	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.67e-05	0.00153	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.67e-05	0.00153	CbGpPWpGaD
Midazolam—GABRA6—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.67e-05	0.00153	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CHST14—thyroid cancer	5.63e-05	0.00152	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—MINPP1—thyroid cancer	5.6e-05	0.00151	CbGpPWpGaD
Midazolam—GABRA4—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.6e-05	0.00151	CbGpPWpGaD
Midazolam—GABRA3—Neuronal System—BRAF—thyroid cancer	5.58e-05	0.0015	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.57e-05	0.0015	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—TPR—thyroid cancer	5.57e-05	0.0015	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—CP—thyroid cancer	5.57e-05	0.0015	CbGpPWpGaD
Midazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	5.55e-05	0.00149	CbGpPWpGaD
Midazolam—GABRA2—Neuronal System—BRAF—thyroid cancer	5.49e-05	0.00148	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—MINPP1—thyroid cancer	5.48e-05	0.00148	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.48e-05	0.00147	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—MINPP1—thyroid cancer	5.47e-05	0.00147	CbGpPWpGaD
Midazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	5.47e-05	0.00147	CbGpPWpGaD
Midazolam—GABRB3—Neuronal System—BRAF—thyroid cancer	5.45e-05	0.00147	CbGpPWpGaD
Midazolam—GABRG2—Neuronal System—BRAF—thyroid cancer	5.35e-05	0.00144	CbGpPWpGaD
Midazolam—GABRR1—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.31e-05	0.00143	CbGpPWpGaD
Midazolam—SLC22A1—Transmission across Chemical Synapses—BRAF—thyroid cancer	5.23e-05	0.00141	CbGpPWpGaD
Midazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	5.17e-05	0.00139	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	5.17e-05	0.00139	CbGpPWpGaD
Midazolam—GABRB2—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.12e-05	0.00138	CbGpPWpGaD
Midazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	5.11e-05	0.00138	CbGpPWpGaD
Midazolam—GABRR2—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.07e-05	0.00136	CbGpPWpGaD
Midazolam—GABRQ—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.07e-05	0.00136	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.97e-05	0.00134	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.88e-05	0.00131	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—HPGD—thyroid cancer	4.88e-05	0.00131	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.87e-05	0.00131	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.8e-05	0.00129	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.77e-05	0.00128	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NDUFA13—thyroid cancer	4.76e-05	0.00128	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.68e-05	0.00126	CbGpPWpGaD
Midazolam—GABRA1—Neuronal System—BRAF—thyroid cancer	4.68e-05	0.00126	CbGpPWpGaD
Midazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	4.67e-05	0.00126	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NDUFA13—thyroid cancer	4.66e-05	0.00126	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NDUFA13—thyroid cancer	4.65e-05	0.00125	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—HPGD—thyroid cancer	4.54e-05	0.00122	CbGpPWpGaD
Midazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	4.54e-05	0.00122	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CHST14—thyroid cancer	4.48e-05	0.0012	CbGpPWpGaD
Midazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	4.46e-05	0.0012	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CHST14—thyroid cancer	4.38e-05	0.00118	CbGpPWpGaD
Midazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	4.38e-05	0.00118	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CHST14—thyroid cancer	4.38e-05	0.00118	CbGpPWpGaD
Midazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	4.35e-05	0.00117	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—SLC5A5—thyroid cancer	4.34e-05	0.00117	CbGpPWpGaD
Midazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	4.27e-05	0.00115	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—HRAS—thyroid cancer	4.26e-05	0.00115	CbGpPWpGaD
Midazolam—GABRG3—Transmission across Chemical Synapses—HRAS—thyroid cancer	4.17e-05	0.00112	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.17e-05	0.00112	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—MINPP1—thyroid cancer	4.13e-05	0.00111	CbGpPWpGaD
Midazolam—GABRB1—Transmission across Chemical Synapses—HRAS—thyroid cancer	4.11e-05	0.00111	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.09e-05	0.0011	CbGpPWpGaD
Midazolam—GABRR1—Neuronal System—HRAS—thyroid cancer	4.07e-05	0.0011	CbGpPWpGaD
Midazolam—SLC22A1—Neuronal System—BRAF—thyroid cancer	4e-05	0.00108	CbGpPWpGaD
Midazolam—GABRA6—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.89e-05	0.00105	CbGpPWpGaD
Midazolam—GABRR2—Neuronal System—HRAS—thyroid cancer	3.88e-05	0.00105	CbGpPWpGaD
Midazolam—GABRQ—Neuronal System—HRAS—thyroid cancer	3.88e-05	0.00105	CbGpPWpGaD
Midazolam—GABRA4—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.84e-05	0.00103	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—AKT1—thyroid cancer	3.76e-05	0.00101	CbGpPWpGaD
Midazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	3.74e-05	0.00101	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PPARG—thyroid cancer	3.68e-05	0.000991	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—RXRA—thyroid cancer	3.65e-05	0.000982	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—HPGD—thyroid cancer	3.61e-05	0.000971	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—HPGD—thyroid cancer	3.53e-05	0.000951	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—HPGD—thyroid cancer	3.53e-05	0.000949	CbGpPWpGaD
Midazolam—GABRB2—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.51e-05	0.000946	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NDUFA13—thyroid cancer	3.51e-05	0.000945	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.5e-05	0.000943	CbGpPWpGaD
Midazolam—CYP3A4—Biological oxidations—RXRA—thyroid cancer	3.46e-05	0.000932	CbGpPWpGaD
Midazolam—GABRA5—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.41e-05	0.000919	CbGpPWpGaD
Midazolam—GABRA3—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.35e-05	0.000902	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CHST14—thyroid cancer	3.3e-05	0.000889	CbGpPWpGaD
Midazolam—GABRA2—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.29e-05	0.000887	CbGpPWpGaD
Midazolam—GABRB3—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.27e-05	0.000881	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	3.26e-05	0.000878	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	3.26e-05	0.000878	CbGpPWpGaD
Midazolam—GABRG2—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.21e-05	0.000865	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.21e-05	0.000864	CbGpPWpGaD
Midazolam—GABRG3—Neuronal System—HRAS—thyroid cancer	3.2e-05	0.000861	CbGpPWpGaD
Midazolam—GABRB1—Neuronal System—HRAS—thyroid cancer	3.15e-05	0.000848	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	3.02e-05	0.000813	CbGpPWpGaD
Midazolam—GABRA6—Neuronal System—HRAS—thyroid cancer	2.98e-05	0.000802	CbGpPWpGaD
Midazolam—GABRA4—Neuronal System—HRAS—thyroid cancer	2.94e-05	0.000792	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PTGS2—thyroid cancer	2.9e-05	0.00078	CbGpPWpGaD
Midazolam—GABRA1—Transmission across Chemical Synapses—HRAS—thyroid cancer	2.81e-05	0.000756	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—TPR—thyroid cancer	2.8e-05	0.000754	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	2.76e-05	0.000742	CbGpPWpGaD
Midazolam—GABRB2—Neuronal System—HRAS—thyroid cancer	2.69e-05	0.000725	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—HPGD—thyroid cancer	2.66e-05	0.000716	CbGpPWpGaD
Midazolam—GABRA5—Neuronal System—HRAS—thyroid cancer	2.61e-05	0.000704	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—TPR—thyroid cancer	2.61e-05	0.000702	CbGpPWpGaD
Midazolam—GABRA3—Neuronal System—HRAS—thyroid cancer	2.57e-05	0.000691	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	2.57e-05	0.000691	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PRKAR1A—thyroid cancer	2.57e-05	0.000691	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—MINPP1—thyroid cancer	2.54e-05	0.000685	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PTEN—thyroid cancer	2.53e-05	0.00068	CbGpPWpGaD
Midazolam—GABRA2—Neuronal System—HRAS—thyroid cancer	2.52e-05	0.000679	CbGpPWpGaD
Midazolam—GABRB3—Neuronal System—HRAS—thyroid cancer	2.51e-05	0.000675	CbGpPWpGaD
Midazolam—GABRG2—Neuronal System—HRAS—thyroid cancer	2.46e-05	0.000663	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.44e-05	0.000658	CbGpPWpGaD
Midazolam—SLC22A1—Transmission across Chemical Synapses—HRAS—thyroid cancer	2.4e-05	0.000647	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.32e-05	0.000624	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PPARG—thyroid cancer	2.3e-05	0.00062	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.24e-05	0.000603	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.16e-05	0.000582	CbGpPWpGaD
Midazolam—GABRA1—Neuronal System—HRAS—thyroid cancer	2.15e-05	0.000579	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—SLC5A5—thyroid cancer	2.1e-05	0.000565	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—TPR—thyroid cancer	2.07e-05	0.000558	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.05e-05	0.000552	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	2.04e-05	0.000549	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CHST14—thyroid cancer	2.03e-05	0.000548	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—TPR—thyroid cancer	2.03e-05	0.000546	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—TPR—thyroid cancer	2.03e-05	0.000545	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PRKAR1A—thyroid cancer	2e-05	0.000538	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	1.99e-05	0.000536	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—SLC5A5—thyroid cancer	1.95e-05	0.000525	CbGpPWpGaD
Midazolam—SLC22A1—Neuronal System—HRAS—thyroid cancer	1.84e-05	0.000496	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PTGS2—thyroid cancer	1.81e-05	0.000488	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—RXRA—thyroid cancer	1.76e-05	0.000474	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.72e-05	0.000463	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—RXRA—thyroid cancer	1.64e-05	0.000441	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—HPGD—thyroid cancer	1.64e-05	0.000441	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PTEN—thyroid cancer	1.58e-05	0.000425	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—SLC5A5—thyroid cancer	1.55e-05	0.000418	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—TPR—thyroid cancer	1.53e-05	0.000411	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.53e-05	0.000411	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—SLC5A5—thyroid cancer	1.52e-05	0.000409	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—SLC5A5—thyroid cancer	1.52e-05	0.000408	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.5e-05	0.000405	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—AKT1—thyroid cancer	1.46e-05	0.000392	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—RXRA—thyroid cancer	1.3e-05	0.000351	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.29e-05	0.000347	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—RXRA—thyroid cancer	1.28e-05	0.000344	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—RXRA—thyroid cancer	1.27e-05	0.000343	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.14e-05	0.000308	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PPARG—thyroid cancer	1.11e-05	0.0003	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PPARG—thyroid cancer	1.04e-05	0.000279	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—RXRA—thyroid cancer	9.61e-06	0.000259	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—TPR—thyroid cancer	9.42e-06	0.000253	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	9.26e-06	0.000249	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—AKT1—thyroid cancer	9.11e-06	0.000245	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PTGS2—thyroid cancer	8.75e-06	0.000236	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PPARG—thyroid cancer	8.23e-06	0.000222	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PTGS2—thyroid cancer	8.15e-06	0.000219	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PPARG—thyroid cancer	8.06e-06	0.000217	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PPARG—thyroid cancer	8.04e-06	0.000217	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PTEN—thyroid cancer	7.63e-06	0.000205	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PTEN—thyroid cancer	7.1e-06	0.000191	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—SLC5A5—thyroid cancer	7.05e-06	0.00019	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PTGS2—thyroid cancer	6.47e-06	0.000174	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PTGS2—thyroid cancer	6.34e-06	0.000171	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PTGS2—thyroid cancer	6.33e-06	0.00017	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PPARG—thyroid cancer	6.07e-06	0.000163	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—RXRA—thyroid cancer	5.92e-06	0.000159	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PTEN—thyroid cancer	5.65e-06	0.000152	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PTEN—thyroid cancer	5.53e-06	0.000149	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PTEN—thyroid cancer	5.52e-06	0.000149	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PTGS2—thyroid cancer	4.77e-06	0.000129	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—AKT1—thyroid cancer	4.4e-06	0.000118	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PTEN—thyroid cancer	4.16e-06	0.000112	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—AKT1—thyroid cancer	4.09e-06	0.00011	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PPARG—thyroid cancer	3.74e-06	0.000101	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—AKT1—thyroid cancer	3.25e-06	8.76e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—AKT1—thyroid cancer	3.19e-06	8.58e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—AKT1—thyroid cancer	3.18e-06	8.56e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.94e-06	7.92e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PTEN—thyroid cancer	2.57e-06	6.91e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—AKT1—thyroid cancer	2.4e-06	6.46e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—AKT1—thyroid cancer	1.48e-06	3.98e-05	CbGpPWpGaD
